ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ABIONYX Pharma Announces That the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM) Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

January 3, 2022 GMT

TOULOUSE, France--(BUSINESS WIRE)--Jan 3, 2022--

ABIONYX Pharma ( FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces that the French Drug Safety Agency (Agence Nationale de Sécurité du Médicament or ANSM), granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 disease.

Access the complete press release

About ABIONYX Pharma

ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20220103005317/en/

CONTACT: NewCap

Investor relations

Louis-Victor Delouvrier

abionyx@newcap.eu

+33 (0)1 44 71 98 53NewCap

Media relations

Arthur Rouillé

abionyx@newcap.eu

+33 (0)1 44 71 00 15

KEYWORD: EUROPE UNITED STATES NORTH AMERICA FRANCE MASSACHUSETTS

INDUSTRY KEYWORD: FDA HEALTH INFECTIOUS DISEASES GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: ABIONYX Pharma

Copyright Business Wire 2022.

PUB: 01/03/2022 12:14 PM/DISC: 01/03/2022 12:14 PM

http://www.businesswire.com/news/home/20220103005317/en